Spyre Therapeutics, Inc. (SYRE)
90.25
-2.43
(-2.62%)
USD |
NASDAQ |
Sep 18, 16:00
90.21
-0.04
(-0.04%)
After-Hours: 20:00
Spyre Therapeutics Cash from Investing (Quarterly) : -297.90M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -297.90M |
| March 31, 2026 | 56.58M |
| December 31, 2025 | -247.41M |
| September 30, 2025 | 25.00M |
| June 30, 2025 | 79.00M |
| March 31, 2025 | -0.061M |
| December 31, 2024 | -170.54M |
| September 30, 2024 | 42.74M |
| June 30, 2024 | -120.52M |
| March 31, 2024 | -104.96M |
| December 31, 2023 | -35.27M |
| September 30, 2023 | -97.63M |
| June 30, 2023 | 6.76M |
| March 31, 2023 | 17.75M |
| December 31, 2022 | 14.00M |
| September 30, 2022 | 16.50M |
| June 30, 2022 | 0.75M |
| March 31, 2022 | 25.76M |
| December 31, 2021 | 9.663M |
| September 30, 2021 | 5.777M |
| June 30, 2021 | -47.36M |
| March 31, 2021 | 9.30M |
| December 31, 2020 | 28.62M |
| Date | Value |
|---|---|
| September 30, 2020 | 5.784M |
| June 30, 2020 | -56.76M |
| March 31, 2020 | 14.75M |
| December 31, 2019 | 10.33M |
| September 30, 2019 | 16.01M |
| June 30, 2019 | -42.01M |
| March 31, 2019 | 13.94M |
| December 31, 2018 | -2.132M |
| September 30, 2018 | 1.399M |
| June 30, 2018 | -19.20M |
| March 31, 2018 | 4.702M |
| December 31, 2017 | 4.844M |
| September 30, 2017 | -6.286M |
| June 30, 2017 | 4.524M |
| March 31, 2017 | -25.61M |
| December 31, 2016 | 2.559M |
| September 30, 2016 | -15.45M |
| June 30, 2016 | 1.927M |
| March 31, 2016 | -1.192M |
| December 31, 2015 | -0.51M |
| September 30, 2015 | -3.42M |
| June 30, 2015 | -0.024M |
| March 31, 2015 | -0.02M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AbbVie, Inc. | -1.197B |
| Incyte Corp. | -51.79M |
| SELLAS Life Sciences Group, Inc. | 0.00 |
| BridgeBio Pharma, Inc. | 17.89M |
| Relay Therapeutics, Inc. | -353.03M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -70.16M |
| Cash from Financing (Quarterly) | 432.89M |
| Free Cash Flow | -209.47M |
| Free Cash Flow Per Share (Quarterly) | -0.828 |
| Free Cash Flow to Equity (Quarterly) | -70.16M |
| Free Cash Flow to Firm (Quarterly) | -70.16M |
| Free Cash Flow Yield | -3.10% |